Cash Flow Statement
Growth Metrics

Anika Therapeutics (ANIK) Cash from Investing Activities (2016 - 2026)

Anika Therapeutics has reported Cash from Investing Activities over the past 17 years, most recently at -$1.2 million for Q1 2026.

  • Quarterly Cash from Investing Activities fell 174.1% to -$1.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$3.3 million through Mar 2026, up 31.77% year-over-year, with the annual reading at -$401000.0 for FY2025, 95.19% up from the prior year.
  • Cash from Investing Activities was -$1.2 million for Q1 2026 at Anika Therapeutics, down from $198000.0 in the prior quarter.
  • Over five years, Cash from Investing Activities peaked at $1.7 million in Q1 2025 and troughed at -$3.4 million in Q2 2024.
  • The 5-year median for Cash from Investing Activities is -$1.5 million (2023), against an average of -$1.3 million.
  • Year-over-year, Cash from Investing Activities plummeted 176.47% in 2022 and then soared 192.48% in 2025.
  • A 5-year view of Cash from Investing Activities shows it stood at -$2.5 million in 2022, then increased by 27.24% to -$1.8 million in 2023, then grew by 28.97% to -$1.3 million in 2024, then skyrocketed by 115.15% to $198000.0 in 2025, then plummeted by 725.76% to -$1.2 million in 2026.
  • Per Business Quant, the three most recent readings for ANIK's Cash from Investing Activities are -$1.2 million (Q1 2026), $198000.0 (Q4 2025), and -$1.7 million (Q3 2025).